Breakout Sessions : Clinical and Economic Value of Personalized Cancer Treatment

jun 6, 2019: 9 a.m. - 10:15 a.m.
116, Level 100

Personalized Medicine in cancer care rests on the assumption that genomic profiling can aid in treatment management decisions for patients, yielding both clinical value for patients and economic value for the system. However, genomic profiling technologies are relatively new and the evidence for their clinical and economic utility is limited. Most payers and providers require more evidence to adapt policies and procedures that will lead to widespread access of next generation sequencing (NGS) based diagnostics in clinical practice. This session will feature a discussion on the clinical utility and economic value of NGS-based diagnostic testing in cancer care, including the evidence needed for provider and payer decision-making. Panelists will highlight data sources and original research results that will provide clinical utility and health economic value evidence of genomic profiling technologies.


Michael Sherman
Chief Medical Officer ...

Neal Meropol
Vice President, Resear...

Lotte Steuten
Vice President and Hea...

Daryl Pritchard
Senior Vice President,...

Ammar Qadan
VP Global Market Access